472 BDB001, a toll-like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously in combination with atezolizumab and shows clinical responses in advanced solid tumors

• Alexander Chung,
• Omid Hamid,
• Manish Patel,
• Drew Rasco,
• Robert Andtbacka,
• Anthony Tolcher,
• Melissa Johnson,
• David Sommerhalder,
• Lixin Li

Affiliations

Alexander Chung

3 Duke-NUS Medical School, Singapore

Omid Hamid

Cedars-Sinai Medical Center Angeles Clinic and Research Institute, Santa Monica, California, USA

Manish Patel

General Medicine, University Hospital Wishaw, Wishaw, UK

Drew Rasco

2The START Center for Cancer Care, San Antonio, TX, USA

Robert Andtbacka

Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA

Anthony Tolcher

6Next Onoclogy, San Antonio, TX, USA

Melissa Johnson

3Sarah Cannon Research Institute, Nashville, TN, USA

David Sommerhalder

4NEXT Oncology, San Antonio, TX, USA

Lixin Li

6Seven and Eight Biopharmaceuticals Inc, Edison, NJ, USA